莫沙必利联合雷贝拉唑治疗反流性食管炎临床效果研究

Clinical effect exploration of Mosapride combined with Rabeprazole in the treatment of reflux esophagitis

目的研究莫沙必利联合雷贝拉唑治疗反流性食管炎的临床效果。方法将2015年1月至2016年1月本院收治的108例反流性食管炎患者按照随机数表法分为联合组和对照组。联合组患者给予莫沙必利联合雷贝拉唑治疗,对照组患者给予雷贝拉唑治疗。4周为一疗程,两组患者均治疗2个疗程。比较治疗后两组患者疗效及复发情况。结果两组患者胃脘不适、反酸、疼痛、胸骨后烧灼感持续时间比较均无显著差异(P>0.05)。治疗8周时,联合组治疗有效率显著高于对照组(P<0.05)。随访第24周和第48周时,联合组患者复发率均明显低于对照组(P<0.01)。两组患者不良反应发生率比较无显著差异(P>0.05)。结论莫沙必利可提高雷贝拉唑治疗反流性食管炎的效果,同时降低复发率,但其效果需较长时间用药才能体现。

ObjectiveTo explore the clinical e？ect of Mosapride combined with Rabeprazole in the treatment of reflux esophagitis. Method108 cases with reflux esophagitis from January 2015 to January 2016 in our hospital were divided into combined group and control group according to the random number table method. Patients in combined group were treated with Mosapride combined with Rabeprazole, while patients in control group were treated with Rabeprazole. 4 weeks for 1 course and all patients were treated with 2 courses. The curative e？ect and recurrence after treatment between the two groups were compared. ResultThere were no signi？cant di？erences on the symptoms last time of stomach discomfort, acid regurgitation, pain and retrosternal burning sensation between the groups （P〉0.05）. After 8 weeks for treatment, e？ective rate of combined group was signi？cantly higher than that of control group （P〈0.05）. 24 weeks and 48 weeks of follow-up, combined the recurrence rate of combined group was signi？cantly lower than control group （P 〈 0.01）. There was no signi？cant di？erence in the incidence of adverse reactions between the two groups （P 〉 0.05）. ConclusionMosapride can improve the clinical e？ect of Rabeprazole in the treatment of re？ux esophagitis and reduce the recurrence rate, but the e？ect need a long time for using medicine.